Welcome to our dedicated page for Agilon Health SEC filings (Ticker: AGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
agilon health, inc. filings document the company’s value-based healthcare services business, governance matters, capital structure and operating results. Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, executive appointment and compensation arrangements, and material definitive agreements, including amendments to the company’s credit agreement.
Definitive proxy statements cover shareholder voting matters, board governance and executive compensation. The filing record also includes capital-structure disclosures, such as a certificate amendment related to a reverse stock split of common stock, along with risk-factor and material-event disclosures relevant to agilon’s physician-partnership model and payor contracting environment.
Wulf John William reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director John William Wulf received an equity award of 2,133 shares in the form of restricted stock units as compensation. These units vest in full on June 2, 2027, subject to his continued service as a director. After this grant, he beneficially owns 16,765 shares, including restricted stock units, reflecting a 1-for-25 reverse stock split of the company’s common stock that became effective on March 30, 2026.
WILLIAMS RONALD A reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Ronald A. Williams received a grant of 2,133 restricted stock units of common stock, with no cash price per share reported. These units vest in full on June 2, 2027, subject to his continued service as a director.
After this award, Williams beneficially owns 149,141 shares of agilon health common stock, including restricted stock units. The holdings figure reflects a 1-for-25 reverse stock split of the company’s issued and outstanding common stock that became effective on March 30, 2026.
McLoughlin Karen reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Karen McLoughlin reported receiving an equity award of 2,133 shares of common stock in the form of restricted stock units. These units vest in full on June 2, 2027, if she continues serving as a director through that date.
After giving effect to a 1-for-25 reverse stock split effective March 30, 2026, her beneficial ownership, including restricted stock units, totals 8,207 shares of common stock.
agilon health, inc. director Diana McKenzie received an equity grant in the form of restricted stock units. She acquired 2,133 shares of Common Stock at no cash cost as a grant or award, increasing her direct beneficial ownership to a total of 7,633 shares, including restricted stock units. The RSUs vest in full on June 2, 2027, as long as she continues to serve as a director. The ownership figure reflects the company’s 1-for-25 reverse stock split of its common stock that became effective on March 30, 2026.
Mansukani Sharad reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Sharad Mansukani received a grant of 2,133 shares of Common Stock in the form of restricted stock units. These units vest in full on June 2, 2027, contingent on his continued service as a director.
After this award, he beneficially owns 56,242 shares, which include restricted stock units and reflect the company’s 1-for-25 reverse stock split that became effective on March 30, 2026. This filing reflects routine equity compensation rather than an open‑market trade.
Battaglia Silvana reported acquisition or exercise transactions in this Form 4 filing.
agilon health, inc. director Silvana Battaglia received an equity award of 2,133 restricted stock units, granted at no cash cost and reported as Common Stock. These RSUs vest in full on June 2, 2027, if she continues serving as a director. Following this grant, her beneficial ownership is 7,926 shares, which includes restricted stock units and reflects a 1-for-25 reverse stock split that became effective on March 30, 2026.
agilon health, inc. reported the results of its annual stockholder meeting held on June 2, 2026. Stockholders elected three Class II directors—Diana McKenzie, Karen McLoughlin, and Ronald Williams—to serve until the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
agilon health, inc. Chief Accounting Officer Timothy Gertsch reported a small, routine tax-related share disposition. On this Form 4, 8 shares of Common Stock were withheld by the company at a price of $86.39 per share to cover income tax obligations on vested restricted stock units. Following this withholding, he holds 14,169 shares directly, which still include restricted stock units. The filing clarifies this was not an open-market sale.
agilon health, inc. Schedule 13G reports that AQR Capital Management, LLC and its parent AQR Capital Management Holdings, LLC beneficially own 974,897 shares of common stock, representing 5.87% of the class. The filings list 894,587 shares of shared voting power and 974,897 shares of shared dispositive power.
The Goldman Sachs Group, Inc. filed a Schedule 13G disclosing shared beneficial ownership of 1,018,303.08 shares of Agilon Health, Inc. common stock as of 03/31/2026. The filing shows shared voting and shared dispositive power of 1,018,278.08 and 1,018,303.08 respectively, representing 6.1% of the class. The filing is a joint submission with Goldman Sachs & Co. LLC and includes exhibit disclosures identifying the reporting subsidiary and the joint filing agreement.